Given the favorable clinical activity of crizotinib, ROS1 TKI therapy has become the first-line treatment for advanced non-small cell lung cancer (NSCLC) patients initially testing positive for ROS1 fusion [22, 23]. Here, ROS1 is linked to non-small cell lung carcinoma.